P/E của cổ phiếu GILD là bao nhiêu?

Gilead Sciences Inc (GILD) hiện giao dịch ở mức P/E 17.69 lần.

ROE của cổ phiếu GILD là bao nhiêu?

Gilead Sciences Inc có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 39.19%.

Tỷ suất cổ tức của GILD là bao nhiêu?

Gilead Sciences Inc có tỷ suất cổ tức 2.40%.

Điểm chất lượng (Quality Score) của GILD là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của GILD ở mức 92/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu GILD không?

Điểm AI Timing của GILD là 50/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu GILD thuộc ngành nào?

Gilead Sciences Inc được xếp vào ngành Healthcare >> Drug Manufacturers - General trên sàn NASDAQ

Cổ phiếu GILD (NASDAQ) | GILEAD SCIENCES INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

GILD AI Analysis Summary

Our AI summary for GILD: Gilead Sciences Inc (NASDAQ), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 17.69, ROE of 39.19%, a dividend yield of 2.40%. Its financial Quality Score stands at 92/100 — fundamentals stronger than most of the market. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

GILD

Gilead Sciences Inc

USD 130.21

0.94 (0.72%) Day Change

Watchlist Portfolio Compare Chart

17.69

P/E

0.94

D/E

39.2%

ROE

16.4%

ROA

2.40%

Div Yield

0.03

PEG

GILEAD SCIENCES INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 130.21 Price 0.94 (0.72%) Day Change	NEWS SCORE: 99

GILD Chất lượng tổng thể của cố phiếu Xuất sắc ( Chất lượng = 92) nhưng Thời điểm mua ...(Sign In to See)...

Loading chart...

92 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: ROA quá thấp so với ROE

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Khá , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Rất tốt , ...

Yếu tố Chất lượng

63%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	570
Magic Formula Rank by ROE	570
Magic Formula Rank by ROIC	702
Price	130.21
PBV / Sector	6.96 / 2.68
Earning Per Share	7.36

PE / Sector	17.69 / 27.65
PEG or PE/Growth / Sector	0.03 / 0.28 GREAT
Average 1M Daily Value	820.59 M
Average 1W Daily Value	865.55 M

Yếu tố Kỹ thuật

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

56%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

81%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	30.99 / 17.30 GREAT
NPM Average (%) / Sector	19.86 / 17.60 GREAT
NPM Change Average (%) / Sector	392.71 / 92.67 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	16.38 / 8.73 GOOD
ROA Average (%) / Sector	9.60 / 8.56
ROA Change Average (%) / Sector	405.01 / 94.23 GREAT
ROE (%) / Sector	39.19 / 26.78 GREAT
ROE Average (%) / Sector	25.12 / 13.05 GREAT
ROE Change Average (%) / Sector	334.73 / 96.64 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

12%

Dividend (%) / Sector	2.40 / 2.40
Dividend Average (%) / Sector	3.24 / 3.39
Dividend Change Average (%) / Sector	-10.22 / 4.92

Chi tiết đăng ký

Analyze Date	2026-08-01 07:59:54
Symbol	GILD
Name	GILEAD SCIENCES INC
Sector	Healthcare >> Drug Manufacturers - General
Market	NASDAQ
Listed Shares	1,241.57 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	162,993.29 / 256,404.20

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 333 Lakeside Drive, Foster City, CA, United States, 94404

Phone: 650 574 3000

Website: https://www.gilead.com

Employees: 17,000

Sector: Healthcare >> Drug Manufacturers - General

Description: Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.